Weight matters: study probes Obesity's impact on IBD therapy
NCT ID NCT07343726
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how obesity influences treatment response in 120 adults with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Researchers will track whether obese patients respond differently to standard therapies, especially biologics. The goal is to understand if weight affects drug effectiveness and disease outcomes, which could lead to more personalized treatment plans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors tailor IBD treatments based on a patient's weight, potentially improving outcomes for obese individuals.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not apply to all IBD patients or lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE (IBD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could early lipid screening in High-Risk kids prevent future heart attacks?
- Two-Drug cocktail aims to tame stubborn Crohn's disease
- Dutch hospital data reveals hidden patterns in IBD treatment
- Acupuncture points may signal hidden disease activity
- Hypnosis as a hospital treatment for gut disorders?
- Smartwatches may spot IBD flares before symptoms start